News
Public · Published
Schrödinger Raises 2026 ACV and Drug Discovery Revenue Outlook
Schrödinger reported that annual contract value (ACV), a measure of contracted software business, grew 17% year over year in Q3 2026, and drug discovery revenue was $24M. It also raised its full-year 2026 ACV and drug discovery revenue outlook, but provided no revised guidance figures.
Published:
Updated:
What happened
Schrödinger reported that annual contract value (ACV), a measure of contracted software business, grew 17% year over year in Q3 2026, and drug discovery revenue was $24M. It also raised its full-year 2026 ACV and drug discovery revenue outlook, but provided no revised guidance figures.
Confirmed
Global impact / market context
The higher outlook signals management expects stronger full-year performance, but missing revised targets make the expected increase impossible to quantify. ACV growth points to momentum in the software business, while drug discovery revenue reflects a separate source of income; neither figure alone shows overall profitability or cash available.
Analyst inference
The update combines reported Q3 growth with raised full-year expectations, but gives no revised targets or prior-period drug discovery revenue comparison. Investors therefore have limited information to judge the outlook’s scale or connect the reported activity to total revenue, costs, and profit.
Analyst inference
What to watch
- Schrödinger’s revised full-year ACV and drug discovery revenue targets, when provided, would quantify how much management increased its expectations. Analyst inference
- Complete financial statements could show how reported software and drug discovery performance relates to total revenue, costs, and cash available. Analyst inference
- Future quarterly results could indicate whether ACV growth and drug discovery revenue develop in line with the raised full-year outlook. Analyst inference
Evidence
- Original source link unavailable